Teva Pharmaceutical Industries Limited (TEVJF) Fair Value & Analysis
Healthcare · US · Market cap $35.3B
Teva Pharmaceutical Industries Limited
TEVJF · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 19 days ago
Share price +8.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $14.00 – $33.00 · fair‑value band $15.81 – $36.07 · the $33.00 price screens above the $27.35 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Teva Pharmaceutical Industries Limited (TEVJF) currently trades at $33.00, while our model-based Fair Value estimate is $27.35 — implying the stock looks roughly 17.1% overvalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Teva Pharmaceutical Industries Limited generated revenue of $17.3B at a net margin of 9.0%. Revenue grew 2.3% year over year. It earns a return on equity of 21.6%. Net debt stands at $13.5B. Fundamentals as of Jun 24, 2026
Our scenario range runs from $15.81 (bear case) to $36.07 (bull case); at $33.00, the current price sits within that range. The share trades about 11% below its 52-week high and 136% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside — at -17%, TEVJF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Teva Pharmaceutical Industries Limited reported revenue of $18.7B in FY2025 versus $15.9B in FY2021, a compound +4.1%/yr. Reported net income was $1.5B in FY2025, compounding +38.3%/yr from FY2021.
Is TEVJF fairly valued? → Check now
Recent news
- Deckers Brands Announces Conference Call to Review First Quarter Fiscal 2027 Earnings Results
- Teva (TEVA) Stock Looks Discounted On Cash Flow Yet Fair On Earnings
- Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
- Teva (TEVA) Reports Promising Vitiligo Trial Results And Moves Anti IL 15 Drug Forward
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Teva Pharmaceutical Industries Limited (TEVJF) undervalued?
What is the fair value of TEVJF?
What is the quality score of TEVJF?
What is the revenue of Teva Pharmaceutical Industries Limited (TEVJF)?
What is the net profit margin of TEVJF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Teva Pharmaceutical Industries Limited analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.